Xcelience Reduces Time to Phase I Studies by 17 Weeks Using API into Capsule Services

TAMPA, Fla.--(BUSINESS WIRE)--Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA). API into Capsule projects are on average completed 45 percent faster than traditional formulation efforts, and in some specific cases we have saved our clients as much as 17 weeks.

MORE ON THIS TOPIC